Targeted alpha therapy with 212Pb or 225Ac: Change in RBE from daughter migration
Targeted alpha therapy with 212Pb or 225Ac: Change in RBE from daughter migration
复制标题
DOI:
10.1016/j.ejmp.2018.05.020
复制
发表时间:
2018-07-01
影响因子:
3.4
通讯作者:
Bernal, Mario A.
中科院分区:
文献类型:
--
作者:
Ackerman, Nicole L.;Rosales, Liset de la Fuente;Bernal, Mario A.
Targeted alpha-therapy (TAT) could be delivered early to patients who are at a high-risk for developing brain metastases, targeting the areas of the vasculature where tumor cells are penetrating into the brain. We have utilized a Monte Carlo model representing brain vasculature to calculate physical dose and DNA damage from the a-emitters Ac-225 and Pb-212. The micron-scale dose distributions from all radioactive decay products were modeled in Geant4, including the eV-scale interactions using the Geant4-DNA models. These interactions were then superimposed on an atomic-scale DNA model to estimate strand break yields. In addition to Ac-225 having a higher dose per decay than Pb-212, it also has a double strand break yield per decay that is 4.7 +/- 0.5 times that of Pb-212. However, the efficacy of both nuclides depends on retaining the daughter nuclei at the target location in the brain vasculature. The relative biological effectiveness (RBE) of Ac-225 and Pb-212 are similar when the entire decay chains are included, with maxima of 2.7 +/- 0.6 and 2.5 +/- 0.5 (respectively), and RBE values of about 2 to a depth of 80 mu m. If the initial daughter is lost, the RBE of Pb-212 is completely reduced to 1 or lower and the RBE of Ac-225 is approximately 2 only for the first 40 mu m.